Infectious diseases present a formidable global health crisis, leading to widespread illness and loss of life. At our esteemed organization, we remain unwavering in our commitment to driving forward the field of infectious diseases therapeutic development. With an unwavering focus, we provide a comprehensive array of preclinical research services specifically designed to address the complex challenges posed by these diseases.
Introduction to Infectious Disease Therapeutic Development
Infectious diseases encompass a spectrum of disorders triggered by the invasion of pathogenic microorganisms, which disrupt the body's normal physiological processes. These microorganisms can take the form of bacteria, viruses, fungi, or parasites, each capable of inducing a diverse range of illnesses, varying from mild to severe in nature.
Infectious disease therapeutic development refers to the process of discovering, developing, and testing therapies to treat and prevent infectious diseases. It involves various stages, including target identification, drug discovery, preclinical testing, clinical trials, and regulatory approval. The goal is to develop effective treatments that can combat infectious agents, alleviate symptoms, prevent transmission, and improve outcomes.
Fig.1 The global burden of infectious diseases demonstrates the high priority of research into infectious disease drugs. (Kirtane A. R., et al., 2021)
Types of Infectious Disease Therapies
Infectious disease therapy encompasses a range of approaches, each tailored to target specific infectious agents. The following are the main types of infectious disease therapy:
- Antiviral therapies focus on combating viral infections, which can cause diseases such as HIV, influenza, hepatitis, herpes, and COVID-19.
- Antibacterial therapies aim to combat bacterial infections by targeting specific bacterial structures or metabolic pathways.
- Antifungal therapies target the specific mechanisms and structures of fungi to inhibit their growth and spread.
- Antiparasitic therapies aim to eliminate or control parasites within the host.
- Immunotherapies, including monoclonal antibodies and therapeutic vaccines, can be effective against viral, bacterial, fungal, and parasitic infections.
Table 1 Developmental pipeline of therapies for infectious diseases. (Zumla A., et al., 2016)
| Types of Therapy |
Examples of Therapy |
Developmental Stage |
| Repurposed drug |
Imatinib, verapamil, metformin, ibuprofen |
Preclinical/clinical (early phase) |
| Cytokine therapy |
Interleukin 2, GM-CSF, interferon γ, interleukin 12 (early stage) |
Clinical (late phase) |
| Monoclonal antibody |
Anti-TNFα, anti-interleukin 6, anti-VEGF |
Preclinical/clinical (early phase) |
| Vitamin |
Vitamin D3 |
Clinical (late phase) |
| Cellular therapy |
Autologous mesenchymal stromal cells, T cells |
Clinical (early phase) |
| Repurposed drug |
Valproic acid, vorinostat |
Clinical (early phase) |
| Monoclonal antibody |
Anti-PD-1 |
Preclinical |
| Cellular therapy |
CD19 CAR (for Epstein-Barr virus [EBV] B-cell lymphoma), in-vitro-expanded EBV-specific CD8 CTLs |
Depletion of viral reservoirs to deter progression to lymphoma |
| Cytokine therapy |
Pegylated interferon α and β |
In clinical use |
| Repurposed drug |
Imiquimod, resiquimod |
In clinical use |
| Cytokine therapy |
Interleukin 2, interferon γ (early stage) |
Not yet tested in schistosomiasis |
| Cellular therapy |
MSCs (late stage) |
Not yet tested in trypanosomiasis |
| Recombinant protein |
Peroxiredoxin (as adjuvant to vaccine candidate) |
Preclinical |
Our Services
Developing effective therapeutics for infectious diseases is of vital importance. At our company, we are committed to advancing the field of infectious disease therapeutics through our comprehensive services. By focusing on drug discovery, preclinical testing, and disease model development, our goal is to provide professional, customized, one-stop therapy development solutions to global pharmaceutical companies.
Drawing upon our extensive expertise, our esteemed organization offers a diverse range of therapy development services from a multitude of perspectives, tailored to cater to your unique requirements. With our wealth of experience, we are well-equipped to address various facets of therapy development, ensuring comprehensive and customized solutions.
By Types of Pathogen
By Types of Therapy
The realm of therapeutic development is an ever-evolving landscape, with emerging technologies presenting exciting opportunities for innovation and advancement. At our esteemed organization, we wholeheartedly embrace these cutting-edge advancements to enhance the efficacy and accessibility of therapeutics. If our comprehensive suite of services has piqued your interest, we earnestly encourage you to reach out to us without any reservations.
References
- Kirtane Ameya R., et al. "Nanotechnology approaches for global infectious diseases." Nature Nanotechnology 16.4 (2021): 369-384.
- Zumla Alimuddin, et al. "Host-directed therapies for infectious diseases: current status, recent progress, and future prospects." The Lancet Infectious Diseases 16.4 (2016): e47-e63.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
